NCLT approves Bajaj Healthcare’s acquisition of Genrx Pharmaceuticals
As filed · Bajaj Healthcare Limited has informed the Exchange about General Updates- Receipt of Hon ble NCLT Order approving Acquisition of Genrx Pharmaceuticals Private Limited on a Going Concern Basis
What happened
FactThe NCLT Mumbai Bench approved Bajaj Healthcare’s acquisition of Genrx Pharmaceuticals Private Limited, which is in liquidation, on a going-concern basis through an order dated October 13, 2026. Genrx will become a wholly owned subsidiary of Bajaj Healthcare, subject to implementation of the terms specified in the NCLT order.
Why it matters
CapitSignal interpretationOnce an insolvency process is admitted, control of the company passes from the board to a resolution professional and equity ranks last in any recovery.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Margins
ContradictedGross profit for the quarter stood at INR80.4 crores, up by 16.2% year-on-year compared to INR69.1 crores in Q1 FY26.
Profit after tax from continuing operations stood at about INR13.9 crores, up by 14.1% year-on-year from INR12.2 crores in Q1 last year and broadly remaining stable versus INR13.8 crores in Q4, translating into a PAT margin from continuing operations of 8.4%.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Admission or rejection of the application by the tribunal
- Appointment of a resolution professional
- Claims admitted against the company
- We completed the construction of a plant with the capacity to process approximately 250 MT of opium gum and ab (management committed by FY29)
Evidence
- Bajaj Healthcare Limited has informed the Exchange about General Updates- Receipt of Hon ble NCLT Order approving Acquisition of Genrx Pharmaceuticals Private Limited on a Going Concern Basis(opens the original filing in a new tab)
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
- Earlier statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- The approval clears a key regulatory step for the acquisition and would add Genrx as a wholly owned subsidiary once the NCLT order’s terms are implemented. The filing does not disclose the acquisition consideration or expected financial impact.
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%